Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Annals of Hematology|March 17, 2015
Trends in quality of non-Hodgkin's lymphoma care: is it getting better?J J C Stienen, P B Ottevanger, L Wennekes, et al.
Gynecologic Oncology|March 15, 2022
Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)C C B Post, A M Westermann, I A Boere, et al.
Gynecologic Oncology|March 19, 2024
Demographic, clinical, and sociocognitive determinants related to physical activity and dietary intake in patients with ovarian cancer: A cross-sectional studyYvonne A W Hartman, Marlou-Floor Kenkhuis, Stephanie Stelten, et al.
Gynecologic Oncology|February 25, 2023
The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysisC S E Hendrikse, P M M Theelen, P van der Ploeg, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2012
Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasiaC Lybol, C M G Thomas, E A Blanken, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 23, 2018
Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapyM Bloemendal, M J A Rietveld, W W van Willigen, et al.
Gynecologic Oncology|November 24, 2018
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12F Heitz, P Harter, E Åvall-Lundqvist, et al.
The Lancet. Child & Adolescent Health|April 19, 2024
Long-term neurocognitive, psychosocial, and physical outcomes after prenatal exposure to radiotherapy: a multicentre cohort study of the International Network on Cancer, Infertility, and PregnancyIndra A Van Assche, Kristel Van Calsteren, Jurgen Lemiere, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2014
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancerM E L van der Burg, W Onstenk, I A Boere, et al.
Pageof 5